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Abstract
Emerging evidence reveals enrichment of glioma-initiating cells (GICs) following therapeutic intervention. One factor
known to contribute to this enrichment is cellular plasticity—the ability of glioma cells to attain multiple phenotypes.
To elucidate the molecular mechanisms governing therapy-induced cellular plasticity, we performed genome-wide
chromatin immunoprecipitation sequencing (ChIP-Seq) and gene expression analysis (gene microarray analysis)
during treatment with standard of care temozolomide (TMZ) chemotherapy. Analysis revealed significant
enhancement of open-chromatin marks in known astrocytic enhancers for interleukin-8 (IL-8) loci as well as elevated
expression during anti-glioma chemotherapy. The Cancer Genome Atlas and Ivy Glioblastoma Atlas Project data
demonstrated that IL-8 transcript expression is negatively correlated with GBM patient survival (p= 0.001) and
positively correlated with that of genes associated with the GIC phenotypes, such as KLF4, c-Myc, and HIF2α (p <
0.001). Immunohistochemical analysis of patient samples demonstrated elevated IL-8 expression in about 60% of
recurrent GBM tumors relative to matched primary tumors and this expression also positively correlates with time to
recurrence. Exposure to IL-8 significantly enhanced the self-renewing capacity of PDX GBM (average threefold, p <
0.0005), as well as increasing the expression of GIC markers in the CXCR2 population. Furthermore, IL-8 knockdown
significantly delayed PDX GBM tumor growth in vivo (p < 0.0005). Finally, guided by in silico analysis of TCGA data, we
examined the effect of therapy-induced IL-8 expression on the epigenomic landscape of GBM cells and observed
increased trimethylation of H3K9 and H3K27. Our results show that autocrine IL-8 alters cellular plasticity and mediates
alterations in histone status. These findings suggest that IL-8 signaling participates in regulating GBM adaptation to
therapeutic stress and therefore represents a promising target for combination with conventional chemotherapy in
order to limit GBM recurrence.
Introduction
Glioblastoma (GBM) is the most aggressive and pre-
valent primary brain tumor in adults, with 10,000 new
diagnoses each year. Recurrent tumors, with increased
invasive and resistance capacities, are an inevitability for
GBM patients despite aggressive therapeutic intervention.
Glioma-initiating cells (GICs) are considered a key driver
of primary tumor development, as well as major con-
tributors to tumor recurrence1.
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Recent reports demonstrate that differentiated GBM
cells undergo cellular and molecular changes to acquire
GIC-like states2,3. This cellular plasticity dramatically
complicates our ability to prevent tumor recurrence in the
clinical setting. Our group and others have shown that
therapeutic stress and microenvironmental dynamics
induce cellular plasticity in GBM, driving the conversion
of differentiated GBM cells to GIC states3–5. However, the
exact mechanisms governing post-therapy GBM plasticity
remain unknown. Unraveling the signaling pathways that
drive this plasticity will provide key insight for improving
treatment of GBM.
Using gene expression and bioinformatic analysis, we
identified interleukin-8 (IL-8) as a key player in promoting
post-therapy cellular plasticity. IL-8 enhances the self-
renewal capacity of patient-derived xenograft (PDX) GBM
cells and is elevated in recurrent GBM patient specimens.
Reducing levels of IL-8 in murine models significantly
improved survival and enhanced the efficacy of Temozo-
lomide chemotherapy. We demonstrate that IL-8/
CXCR2 signaling alters the epigenomic landscape in GBM
cells, inducing a GIC-like state and increasing the propor-
tion of GICs after treatment. This study highlights IL-8
signaling as a key influence on GBM plasticity and recur-
rence as well as a potential novel therapeutic target in GBM.
Materials and methods
Cell culture
U251 human glioma cell lines were procured from the
American Type Culture Collection (Manassas, VA, USA).
These cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM; HyClone, Thermo Fisher Scientific,
San Jose, CA, USA) supplemented with 10% fetal bovine
serum (FBS; Atlanta Biologicals, Lawrenceville, GA, USA)
and 1% penicillin–streptomycin (P/S) antibiotic mixture
(Cellgro; Herdon, VA, USA; Mediatech, Herdon, VA,
USA). PDX glioma specimens (GBM43, GBM12, GBM6,
GBM5, and GBM39) were obtained from Dr. C. David
James at Northwestern University and maintained
according to published protocols6. Cells were propagated
in vivo by injection into the flank of nu/nu athymic nude
mice. In vitro experiments with these cells were per-
formed utilizing DMEM supplemented with 1% FBS and
1% P/S antibiotic mixture. All cells were maintained in
humidified atmosphere with CO2 and temperature care-
fully kept at 5% and 37 °C, respectively. Dissociations
were performed enzymatically using 0.05% trypsin and
2.21 mml/L EDTA solution (Mediatech, Corning, Corn-
ing, NY, USA). For experiments, cells were cultured
in their appropriate cell culture media treated with
temozolomide (TMZ; Schering Plough; stock solution
50mmol/L in DMSO), Interleukin-8 (IL-8; Peprotech
Company, Rocky Hill, NJ, USA), or equimolar DMSO
vehicle control. For IL-8 neutralizing antibody
experiments, cells were cultured as described above in the
presence of an IL-8 neutralizing antibody or an IgG
control antibody (R&D Systems, Minneapolis, MN, USA).
Animals
Athymic nude mice (nu/nu; Charles River, Skokie, IL,
USA) were housed according to all Institutional Animal
Care and Use Committee (IACUC) guidelines and in
compliance with all applicable federal and state statutes
governing the use of animals for biomedical research.
Briefly, animals were housed in shoebox cages with no
more than five mice per cage in a temperature and
humidity-controlled room. Food and water were available
ad libitum. A strict 12-h light–dark cycle was maintained.
Intracranial implantation of glioblastoma cells was
performed as previously published7. Briefly, animals
received prophylactic injection of buprenex and meta-
camp via intraperitoneal (i.p.) injection, followed by an i.p.
injection of ketamine/xylazine anesthesia mixture (Henry
Schien, New York, NY, USA). Sedation was confirmed by
foot pinch. Artificial tears were applied to each eye, and
the scalp was sterilized repeatedly with betadine and
ethanol. The scalp was then bisected using a scalpel to
expose the skull. A drill was used to make a small burr
hole above the right frontal lobe (~1-mm in diameter).
Animals were then placed into the stereotactic rig, and a
Hamilton syringe loaded with the cells was brought into
the burr hole. The needle point was lowered 3 mm from
the dura and injection of 5 µL of cell mixture took place
over 1 min. The needle was then raised slightly and left
undisturbed for 1 min to ensure proper release of the cell
mixture. After this, the syringe was carefully removed.
The animal’s head position was maintained, and the skin
of the scalp was closed with sutures (Ethicon, Cincinnati,
OH, USA). Animals were then placed in fresh cages with
circulating heat underneath and monitored for recovery.
All instruments were sterilized with a bead sterilizer
between animals and all other necessary procedures to
maintain a sterile field were performed.
Drug treatments were initiated 7 days after intracranial
implantation. Animals received i.p. injections of either
TMZ (2.5 mg/kg) or equimolar DMSO. Injections were
performed daily for 5 consecutive days.
After injections, animals were monitored daily by a
blinded experimenter for signs of sickness, including
reduction in body weight, lowered body temperature, lack
of grooming, hunched appearance, and behavioral chan-
ges. Animals were euthanized when, in the opinion of the
blinded experimenter, they would not survive until the
next day. Killing of animals was performed according to
Northwestern University guidelines. Briefly, animals were
placed into CO2 chambers and the flow of CO2 was
initiated; the flow rate did not exceed 2 L CO2/min
while the animals were conscious. Whole brains were
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removed and washed in ice-cold phosphate buffer saline
(PBS; Corning, Corning, NY, USA). For those brains uti-
lized for FACS analysis, please see Flow Cytometry section
of the Materials and methods. For those brains employed
for immunohistochemistry analysis, please see the
Immunohistochemistry section of the Materials and
methods.
RNA isolation and microarray
After treatment, cells were dissociated with trypsin and
washed with PBS. RNA extraction was performed using
Qiagen’s RNeasy kit (Qiagen Inc., Germantown, MD,
USA) according to the manufacturer’s instructions.
Quantification of RNA concentrations was performed
using a NanoDrop (Thermo Fisher), and cDNA was
synthesized according to established protocols using
BioRad’s iScript kit using 1000 ng of the total RNA per
sample (BioRad, Hercules, CA, USA). The following
cycles were used in a C1000 Thermal Cycler (BioRad) to
synthesize cDNA: 5 min at 25 °C, 30 min at 42 °C, 5 min at
85 °C, and then temperature stabilized to 4 °C.
For gene expression analysis, the Illumina HumanHT-
12 v3 BeadChip array (Illumina, San Diego, USA) was
used. GBM43 PDX GBM was treated with TMZ (50 μM)
for 8 days. Cells were harvested and mRNA was isolated
as described above. Samples preparation and mRNA array
hybridization was performed according to the manu-
facturer’s guidelines. Illumina Bead Array Reader was
used to read the array and the Illumina’s GenomeStudio
software, as well as the Gene Expression Module was
utilized for data analysis. For quality control, samples with
less than 6000 significant detection probes (detection p-
value < 0.01) were excluded. Normalization was per-
formed for each microarray by using the Lumina package.
A log transformation to base two was also performed on
the normalized data.
In order to determine the expression of various genes of
interest, quantitative polymerase chain reaction (qPCR)
was performed. Briefly, cDNA was diluted and combined
with SYBR green (BioRad) and corresponding primers;
qPCR was then performed using BioRad’s CXF Connect
Real Time machine with the following protocol: initial
activation stage of 10 min at 95 °C, followed by 40 cycles
of 3 min at 95 °C and 30 s at 60 °C. After these cycles were
completed, temperature was brought to 65 °C for 5 min
and then 95 °C for 5 min. Primers were obtained from
Integrative DNA technologies (IDA; Coralville, IA, USA).
Gene Direction Primer sequence (5′- > 3′)
IL8 (CXCL8) Forward AAG CTG GCC GTG GCT CTC TTG
Reverse AGC CCT CTT CAA AAA CTT CTC
continued
Olig2 Forward GCT GCG TCT CAA GAT CAA C
Reverse AGT CGC TTC ATC TCC TCC A
SERPINB2 Forward GAA GCA GGA AAG CAG AAA GAA G
Reverse ACT GCC ACA CAG GAA GAT ATA C
IL6R Forward CTC CTG CCA GTT AGC AGT CC
Reverse TCT TGC CAG GTG ACA CTG AG
BMP2K Forward TGT TGC TGC TGT GTT GCA TGA
Reverse TAT TGG GTC AGG GAC CTC CTC A
Western blot analysis
In order to analyze protein expression in total extracts,
cells were dissociated using trypsin after the appropriate
number of days following treatment, washed with PBS,
and resuspended in mammalian protein extraction
reagent (M-PER; Thermo Fisher) supplemented with
protease and phosphatase inhibitor (PPI; Thermo Fisher)
and EDTA (Thermo Fisher). Cells were then sonicated in
a water bath sonicator for 30 s, followed by a resting phase
of 30 s, for a total of five cycles. Lysates were centrifuged
at 21,000 × g for 10 min in a temperature-controlled
centrifuge held at 4 °C. Supernatants were collected and
protein concentration was determined by Pierce bovine
serum albumin (BSA) assay (Thermo Fisher). In the case
of nuclear and cytoplasmic fractionation, a cytoplasmic
and nuclear protein extraction kit was used (Pierce;
Thermo Fisher). Briefly, cells were dissociated and washed
with PBS. Next, cells were pelleted and resuspended in
ice-cold cytoplasmic extract buffer, and extraction was
performed according to the manufacturer’s instructions.
After collecting the cytoplasmic contents, the remaining
nuclear pellets were pelleted and resuspended in ice-cold
nuclear extraction buffer. Nuclear extraction was com-
pleted as instructed. All samples were stored at −80 °C
when not in use.
Western blot samples were then made with equal
amounts of protein in sodium dodecyl sulfate buffer (SDS
sample buffer; Alfa Aesar, Wood Hill, MA, USA) sup-
plemented with beta-mercapto-ethanol and boiled at
95 °C for 10 min. Proteins were then run through 10%
SDS-polyacrylamide (SDS-PAGE; made in house) by gel
electrophoresis using BioRad equipment (Hercules, CA,
USA). Semidry transfer was then performed to transfer
proteins onto polyvinylidene difluoride (PVDF) mem-
branes (Millipore, Darmstadt, Germany) using a BioRad
transfer machine. Membranes were washed three times in
PBS for 10min each and then blocked with Tris-buffered
saline (TBS) containing 0.05% Tween20 (Sigma Aldrich,
St. Louis, MO, USA) plus 5% powdered milk to limit
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non-specific binding. Primary antibody solutions were
made using 5% BSA solutions supplemented with sodium
azide. Membranes were incubated overnight on a shaker
at 4 °C. The following antibodies were employed: mouse
anti-IL-8 (R&D), rabbit anti-c-Myc (Cell Signaling, Dan-
vers, MA, USA), rabbit anti-Sox2 (Cell Signaling), rabbit
anti-Nanog (Cell Signaling), rabbit anti-LIN28A (Cell
Signaling), rabbit anti-KLF4 (Cell Signaling), mouse anti-
β-actin (Abgent, San Diego, CA, USA), rabbit anti-EZH2
(Cell Signaling), mouse anti-phosphoEZH2 (AbCam,
Cambridge, UK), rabbit anti-Bmi1 (Cell Signaling), rabbit
anti-ring1A (Cell Signaling), rabbit anti-SUZ12 (Cell
Signaling), rabbit anti-H3 (Cell Signaling), rabbit anti-
H3K4methyl3 (Cell Signaling), rabbit anti-H3K27acetyl
(Cell Signaling), rabbit anti-H3K27methyl3 (Cell Signal-
ing), rabbit anti-H3K36methyl3 (Cell Signaling), and
rabbit anti-H2A-Ubiquitin (Cell Signaling). The following
day, membranes were washed and then incubated in
appropriate horseradish peroxidase-conjugated secondary
antibodies, diluted 1:4000 in 5% milk. Membranes were
then washed in TBS-T. Enhanced chemiluminescence
(ECL; Clarity ECL, BioRad) was added to each membrane,
and images were developed using X-ray film (General
Electric, Boston, MA, USA). All densitometry analysis was
performed using ImageJ (National Institutes of Health). β-
Actin levels were determined for all western blots to
ensure proper loading of gels.
Coimmunoprecipitation
For coimmunoprecipitation (Co-IP) experiments, pro-
teins were extracted and quantified as described above.
Then 50–100 µg of proteins were incubated with primary
antibody overnight at 4 °C with gentle rocking. The next
day, anti-rabbit IgG antibodies conjugated to agarose
beads were added to the cell lysates and incubated for at
least 1 h at 22 °C. Next, the mixture was spun down and
washed several times in PBS. Finally, proteins were eluted
from the mixture and loaded into gels, as described above.
Flow cytometry analysis
For in vitro experiments, cells were collected at serial
time points after the beginning of treatment (days 2, 4, 6,
and 8), and fresh surface staining was performed. Next,
cells were treated with fixation and permeabilization
buffers (eBioscience, San Diego, CA, USA) according to
the manufacturer’s instructions. For those cells that were
collected based on surface expression, no fixation or
permeabilization was performed to maintain cell integrity.
After this fixation, intracellular staining was performed
overnight, followed by triplicate washing and the addition
of appropriate secondary antibodies. In vivo studies began
with the killing of tumor-bearing mice and immediate
removal of the whole brain. Brains were washed in ice-
cold PBS, and then bisected down the longitudinal fissure
and right brains (tumor-bearing) were passed through a
70 µM strainer. These single cell suspensions were then
incubated in ACK lysis buffer (Lonza, Walkersville, MA,
USA) for 5 min at 20–25 °C to lysis any blood cells. After
washing with PBS, cells were stained as in in vitro
experiments. Human leukocyte antigen (HLA) staining
was used to identify human tumor cells. All cells were
collected in PBS supplemented with 1% BSA (Fisher Sci-
entific, Fair Lawn, NJ, USA) and sodium azide and kept on
ice until read.
The following antibodies were used: anti-HLA-PB
(1:200; BioLegend, San Diego, CA, USA), anti-CD133-
APC and anti-CD133-PE (2:100; Miltenyi Biotec, Auburn,
CA, USA), anti-CD15-APC (5:100; BioLegend, San Diego,
CA, USA), anti-IL-8 (R&D Systems, Minneapolis, MN,
USA), anti- CXCR1 (R&D Systems, Minneapolis,
MN, USA), and anti-CXCR2 (R&D Systems, Minneapolis,
MN, USA). In addition, we used secondary antibodies,
such as anti-rabbit IgG-FITC (1:500; Invitrogen, Waltham,
MA, USA) and anti-mouse IgG-PB (1:500; Invitrogen,
Waltham, MA, USA). Samples were run on BD LSRFor-
tessa 6-Laser FACS analyzer (WHERE) and analyzed uti-
lizing FlowJo software (TreeStar, Ashland, OR, USA).
For reporter cells, antibody staining was not performed.
Rather, cells were dissociated using trypsin and
washed with PBS. They were then resuspended in PBS
with 1% BSA and sodium azide and kept on ice until
analysis.
Enzyme-linked immunosorbent assay
ELISAs were performed to determine the level of IL-8
protein in cell supernatants. After the noted number of
days since treatment, supernatants were collected and
centrifuged at 1200 × g for 5 min to pellet any cellular
debris. Supernatants were then collected in fresh tubes.
ELISAs were obtained from eBioscience and performed
according to the manufacturer’s instructions. In summary,
supernatants were collected from culture flasks on the
appointed day. Supernatants were then centrifuged to
pellet any floating cell or debris. Supernatants were col-
lected and placed into clean microcentrifuge tubes.
Samples were then added to ELISA plates that had been
coated overnight at room temperature with capture
antibody diluted in coating buffer, washed five times, and
blocked for 1 h. Initial optimization runs of supernatants
from non-treated cells showed that GBM43 expressed
high levels of IL-8, and that supernatants needed to be
diluted 1:20 to ensure signaling within the range of our
standard curve; all other cell lines were diluted 1:5. After
2 h of incubation at room temperature, supernatants were
removed and the ELISA plate was washed five times.
Detection antibody was then added for 1 h, followed by
washing, and the addition of avidin–horseradish perox-
idase solution for 30min. The plate was then washed
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seven times to ensure no false-positive signals were gen-
erated. Tetramethylbenzidine (TMB) solution was added
and incubated for 15 min. Reactions were halted using 1 N
hydrochloric acid. Plates were immediately read using a
BioTek plate reader (Abs450 nm–Abs570 nm). Standard
curves were generated and IL-8 concentration was
determined.
Immunohistochemistry
After whole brains were removed from animal skulls,
they were washed in ice-cold PBS. Brains were then flash
frozen in optimal cutting temperature compound (OCT;
Electron Microscopy Sciences, Hatfield, PA, USA). Sec-
tions, 8 -microns thick, were obtained by cryostat (Leica
Biosystems, Wetzler, Germany) and kept frozen at −30 °C
until IHC was begun. Staining for IL-8 was performed as
follows: sections were allowed to dry at 22 °C for 30min.
Excess OCT compound was then scrapped away from the
margins, and an Immuno-Pen was used to create a border
around each section. After one wash with ice-cold PBS,
sections were fixed with 4% paraformaldehyde (Boston
BioProducts, Boston, MA, USA) for 10min. Sections were
then washed three times with ice-cold PBS. A solution of
1% BSA and 0.3% Triton-X100 was then placed on top of
each section for 1 h to permeabilize and block the section.
Primary mouse anti-IL-8 antibodies (R&D) diluted in 1%
BSA solution with 0.3% Triton-100 were then added and
sections were incubated overnight at 4 °C. The following
day, antibodies were removed and sections were washed
three times with ice-cold PBS. Appropriate secondary
goat anti-mouse IgG conjugated to FITC was diluted
1:2000 in 1% BSA with Triton-X100 and incubated for 1 h
at 22 °C. Sections were then washed with ice-cold PBS
three times. Fluro-Gold with DAPI (Thermo Fisher) was
gently applied to each section and coverslips were care-
fully placed on top.
A Leica microscope was utilized for IHC analysis
(Leica). For each section, tumors were identified by cell
morphology and density. A blinded experimenter ana-
lyzed the slides for IL-8 expression and generated each
image. ImageJ (National Institutes of Health) was used for
final image processing and the generation of images for
publications.
Human sample histology
Human primary and matched recurrent GBM tissues
were obtained from the Northwestern University’s Ner-
vous System Tumor Bank. All patients were consented
according to the Institutional Review Board (IRB) policies
prior to the obtainment of samples. Samples were
formalin-fixed and paraffin-embedded (FFPE). Immuno-
histochemistry of tumor samples was performed on
4-μm-thick sections heated at 60 °C for at least 1 h.
Staining for IL-8 was carried out manually, and antigen
retrieval was performed with a BioCare Medical
Decloaking Chamber using high (LC3) or low pH antigen
retrieval buffer from Dako. Primary antibodies were
incubated for 1 h at room temperature. A secondary
antibody was EnVision-labeled polymer-HRP (horse-
radish peroxidase) anti-mouse or anti-rabbit as appro-
priate. Staining was visualized using 3, 3′-
diaminobenzidine (DAB) chromogen (Dako, K8000).
IL-8 immunohistochemical results on TMAs were
semiquantified on a relative scale from 0 to 3, with 0=
negative and 3= strongest (see Supplementary Fig. 1).
Each tumor was represented by three separate cores on
three separate blocks.
Bioinformatics analysis
We utilized the publicly available The Cancer Genome
Atlas (TCGA) GBM database for all examination of gene
expression. We performed the following analyses: Corre-
lation between IL-8 and all the other genes was deter-
mined by Pearson correlation coefficients. Those genes
with coefficients > 0.5 or <−0.5 and false discovery rate
(FDR) < 0.05 were selected to be correlated with IL-8.
Then non-negative matrix factorization (NMF) was
employed to identify clusters of all the genes that are
correlated with IL-8 using the R package “NMF”8.
Brunet algorithm was used to estimate the factorization.
We performed 40 runs for each value of the factorization
rank r in range 2:7 to build consensus map. The optimal
cluster was determined by the observed cophenetic cor-
relation between clusters, and validated by silhouette plot
and principle component analysis (PCA). Function
“aheatmap” was used for plotting the heatmap and clus-
tering with “euclidean” as the distance measure and
“complete” as the clustering method.
Differences of IL-8 expression among different WHO
grade and subtypes were examined using one-way
ANOVA, and followed by Bonferroni correction for the
multiple comparison.
GBM patients were stratified into IL-8-upregulated and
IL-8-downregulated groups based on IL-8 gene expres-
sion using quartile (Q1, Q3) as split points. Survival
curves were generated via Kaplan–Meier method, and
compared by log-rank test.
For clinical factor comparison, we used the TCGA
U133a dataset. Cox proportional hazards model with
stepwise variable selection was conducted to examine
whether IL-8 could be independent factor for predicting
survival with major clinical variables adjusted. C index
(95% CI) or C statistics was provided to see how well the
models are fitted, and likelihood ratio test was conducted
to compare the multivariable models with and without the
targeted variable.
For expression localization, we utilized the Ivy Glio-
blastoma Atlas Project (IVY GAP; Allen Institute for
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Brain Science, Seattle, WA, USA) and their online plat-
form (glioblastoma.alleninstitue.org).
ChIP-Seq reads underwent FastQC quality analysis
after sequencing and no abnormalities were detected.
Alignment was done using Bowtie2 software, and peak
calling was performed using the MACS2 CallPeak
function with p-value set to 0.05. All ChIP-Seq data
were visualized using Integrated Genomics Viewer
(IGV).
Extreme limiting dilution analysis and neurosphere assays
PDX cells fresh from the flank of nu/nu mice were
washed with PBS and plated in serial dilutions 200, 150,
100, 50, 25, 12, 6, 3 cells per well, 12 wells per dilution,
in neurobasal media (Gibco cat. no. 21103049, Thermo
Fisher) supplemented with the following growth factors:
B27 (without vitamin A, Invitrogen), basic fibroblast
growth factor (10 ng/mL; Invitrogen), epidermal growth
factor (10 ng/mL; Invitrogen), and N2 (Invitrogen)
treated with either PBS or IL-8. A blinded experimenter
examined each well after 7 and 14 days and counted the
number of formed neurospheres with a diameter
greater than 20 cells. These counts were analyzed using
the Walter+ Eliza Hall Institute of Medical Research
outline platform (http://bioinf.wehi.edu.au/software/
elda/). This platform allows for the determination of
stem cell frequency, as well as quantification of differ-
ences between the IL-8 treated and non-treated
samples.
Generation of shRNA constructs
In order to knockdown the expression of IL-8, short-
hairpin RNA (shRNA) constructs were obtained com-
mercially (Genecopoeia, Rockville, MD, USA). All shRNA
constructs expressed IL-8 shRNA under the control of a
CMV promoter and included a GFP construction for
simple identification of successfully transfected cells.
Plasmids for these constructs were packaged into lenti-
viral vectors using X293 cells. Briefly, plasmids and all
necessary transfection reagents were added to low-
passage X293 cells growing as adherent cultures in
DMEM media fortified with 10% FBS and 1% P/S anti-
body mixtures. After 3 days, supernatants were collected
and ultracentrifugation was performed. Viral titration was
determined by sequential dosing of collected viruses in
X293 cells, followed by analysis of GFP expression. After
determination of viral titer, human glioma and PDX cells
were transfected with 25 IU of the lentiviral vector. This
transfection was performed in suspension for 30min at
22 °C with gentle agitation every 5 min. For in vitro
experiments in human glioma cells, cells were propagated
and GFP+ populations were purified using FACS sorting.
IL-8 knockdown was confirmed via ELISA and/or FACS
analysis.
Cell cycle analysis
These analyses were completed using the propidium
iodide/RNase staining buffer (BD Pharmingen, cat. no.
550825) according to the manufacturer’s guidelines.
Briefly, after the desired number of days of treatment with
either DMSO or TMZ, cells were dissociated from the
plate and washed with PBS. They were then treated with
70% ethanol solution as a fixative, followed by permea-
bilization. Cells were then treated with RNase and pro-
teases to ensure maximum DNA staining. After
incubation with these reagents, cells were washed thor-
oughly with PBS. Then, cells were stained with propidium
iodide for 30min at 4 °C. After washing, cells were ana-
lyzed by flow cytometry. Gating strategy was as follows:
SSC-A and FSC-A were plotted and cellular debris was
excluded. Then, SSC-W and FSC-W were plotted to
identify only single cells. Then, SSC-A and PI stainings
were plotted. Unstained controls were used to establish
background signal. Finally, PI staining was plotted as a
histogram. DNA content was assayed, and the progression
of the cell cycle was determined based on the histogram
plot. Any aberrations caused by the introduction of
shRNA constructs were noted and these constructs were
excluded.
Statistical analysis
All statistical analyses were performed using the
GraphPad Prism Software v4.0 (GraphPad Software, San
Diego, CA, USA). Where applicable, one-way ANOVA,
unpaired t test, and log-rank test were applied. Survival
distributions were estimated with the Kaplan–Meier
method. A p-value < 0.05 was considered statistically
significant.
Results
Therapeutic stress increases IL-8 expression in vitro and
in vivo
To investigate if Temozolomide (TMZ) chemotherapy
promotes the adoption of a GIC state via cellular plasti-
city, gene set enrichment analysis (GSEA) using the
Affymetrix platform was performed. Data from PDX
GBM43 cells 4 and 8 days post-treatment with either
vehicle control (DMSO) or physiological doses of TMZ
(50 μM, see Supplementary Fig. 1)9–12 revealed a sig-
nificant (FDR q= 0.08, FWER p-value= 0.046) enrich-
ment of a network of genes responsible for supporting the
GIC phenotype (Fig. 1a)13. Interestingly, gene expression
revealed that interleukin-8 (IL-8) is significantly upregu-
lated post-TMZ therapy (Supplementary Table 1). To
investigate epigenetic plasticity during TMZ therapy, we
performed genome-wide ChIP-Seq analysis of TMZ-
treated PDX GBM43 cells for histone 3 lysine 27
(H3K27) acetylation (ac), a marker of open chromatin,
and H3K27 trimethylation (me3), a maker of closed
Hasan et al. Cell Death and Disease          (2019) 10:292 Page 6 of 17
Official journal of the Cell Death Differentiation Association
chromatin. TMZ significantly augments H3K27ac levels,
but not H3K27me3 levels, at an IL8 enhancer locus
identified in astrocytes. (Fig. 1b, chromosome 4:
74783222–74783418, fold enrichment 3.02 as compared
with input, p-value < 0.0001, FDR= 0.004). Therefore,
TMZ may promote a GIC state by altering the epigenomic
landscape of GBM. Quantitative polymerase chain reac-
tion (qRT-PCR) confirmed that TMZ treatment increased
IL-8 mRNA levels in a time-dependent manner
(Figure 1c) (***p < 0.0001). To validate this effect in vivo,
immunofluorescence analysis was performed on a
previously established orthotropic recurrent GBM model,
which confirmed that recurrent tumors had increased IL-
8 expression (Fig. 1e). Considering the ability of therapy to
induce both IL-8 expression and a GIC state, we exam-
ined if alterations in cell state can influence such
expression without therapy. PDX lines were cultured in
GIC maintenance media (neurobasal media supplement
with appropriate growth factors) or differentiation con-
dition media (1% FBS) with or without TMZ (50 μM).
Even without any chemotherapy, culturing GBM PDX
lines in the GIC maintenance media significantly elevated
Fig. 1 Therapeutic stress increases IL-8 expression. a PDX GBM43 cells were treated with TMZ (50 μM), and RNA collected after 4 or 8 days.
Microarray analysis using Affymetrix platform was performed. Gene set enrichment analysis (GSEA) for genes known to support and maintain the GIC
phenotype13 and demonstrated significance increase after 8 days [day 4 FDR q 0.82 and day 8 FDR 0.08 and FWER p-value 0.046, TMZ-treated cells as
compared with DMSO controls]. b Whole-genome ChIP-seq analysis of H3K27 trimethylation (H3K27me) and H3k27 acetylation mark (H2K27ac) on
PDX GBM43 following 4 days treatment with TMZ or vehicle control. Top two tracks represent the BET file showing significant enrichment of histone
mark relative to DMSO control. Bottom two lanes represent WIG file showing significant enrichment peak. Analysis of three established astrocyte
enhancer tracks for the IL-8 gene showed no changes in H3K27me3; however, they did show significant change in #3 enhancer region [Chr.
4 :74783222–74783418, fold enrichment 3.2 relative to IgG input. p < 0.0001. FDR= 0.004]. Right bottom inset image shows zoomed in view of the #3
enhancer region. Left bottom inset image represents overlayed peaks for TMZ and DMSO control. c Expression of IL-8 mRNA after exposure to 50 µM
TMZ was determined by quantitative real-time polymerase chain reaction (qPCR) after treatment with TMZ across 8 days. All IL-8 values were
normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Bars represent means from three independent experiments and error bars
represent the standard deviation. Multiple Student's t tests were performed. **p < 0.01, ***p < 0.001. d Immunohistochemistry was performed on
mouse brains with intracranial xenografts of GBM43. 1.5 × 105 GBM43 PDX cells were implanted to establish orthotropic xenograft tumors. Animals
received 2.5 mg/kg of either DMSO or TMZ for five consecutive days, beginning 7 days after tumor implantation. Animals were killed 5 days after the
cessation of treatment, and whole brains were extracted, flash frozen, then sectioned (8 µm) and analyzed by immunofluorescence. 4′-6-diamidino-2-
phenylindole (DAPI) stained DNA (blue) in the nuclei and allophycocyanin-conjugated secondary (orange) antibody was used against primary
antibody for IL-8. Dotted lines represent the edge of the tumor based on cell density and morphology. e–f PDX GBM xenografts were harvested and
immediately plated in either mild differentiation media (DMEM containing 1% FBS) or GIC maintenance media (neurobasal supplemented with FGF
and EGF). Cells were then treated with either DMSO or TMZ (50 μM). After 4 days, IL-8 levels were determined by ELISA. g GBM cells were treated with
physiologically relevant dose of TMZ (50 μM), carmustine (BCNU, 100 μM), or equimolar DMSO. After 24 h, conditioned media was collected and IL-8
levels were quantified by ELISA. Bars represent means from three independent experiments and error bars represent the standard deviation. Multiple
Student's t tests were performed. **p < 0.01, ***p < 0.001
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the expression of IL-8 expression measured by enzyme-
linked immunosorbent assay (ELISA, Fig 1c) (****p <
0.0001). Proneural subtype GBM43 and classical subtype
GBM6 expressed about 20- and 200-fold higher IL8,
respectively, in the GIC maintenance media. TMZ expo-
sure induced IL8 expression in both culture conditions
(****p < 0.0001). Moreover, this induction was specific to
TMZ, as another anti-glioma alkylating agent BCNU
failed to promote IL8 expression in any GBM lines tested
(***p < 0.001 and ****p < 0.0001, Fig. 1g). Based on these
observations, we investigated the role of IL-8 in promot-
ing therapy-induced cellular plasticity and disease recur-
rence. Critically, we utilized differentiation condition
media (1% FBS or neural basal media with BMP2), as
these conditions initiate differentiation of GBM cells and
enable us to observe how stimuli induce dedifferentiation
to the GIC state during therapy5,7. Culturing cells in a
GIC-promoting media (neurobasal supplemented with
EGF and FGF) would be inappropriate for this study, as it
would force the cells to a GIC state and mask GIC-
inducing effects of our experimental manipulations.
In silico analysis establishes IL-8 importance in GBM
progression and patient outcomes
In order to examine the contribution of IL-8 to GBM
clinical progression, we employed the Cancer Genome
Atlas (TCGA) patient gene expression dataset, including
wild-type and IDH mutation tumors. Analysis showed
that IL-8 transcript expression is elevated in World
Health Organization (WHO) Grade IV glioma (GBM)
(Fig. 2a, IL-8 transcript expression, Grade IV vs. Grade II
p < 0.0001; Grade IV vs. Grade III, p < 0.0001). Next,
GBM patients were stratified based on IL-8 mRNA
expression using quartile (Q1, Q3) split points; the lowest
IL-8 quartile exhibited significantly higher median survi-
val (Fig. 2b) (All GBM: IL-8-down 15.1 months, IL-8-up
12.6 months, hazard ratio (HR) [95% CI]= 0.71 [0.54,
0.93], log-rank p-value= 0.0112). This association
between IL-8 and survival was especially pronounced in
patients with proneural GBM tumors (Fig. 2d) (proneural
subtype: IL-8-down 20.7 months, IL-8-up 9.3 months, HR
[95% CI]= 0.54 [0.33, 0.87], log-rank p-value= 0.0109).
Multivariable stepwise Cox proportional hazards model
confirmed IL-8 as an independent prognostic survival
factor in all GBM patients, specifically those with pro-
neural tumors (Figs 2b–d, right panel) (HR [95% CI]: all
GBM 1.07 [1.01, 1.14], p= 0.0467; proneural subtype 1.19
[1.04, 1.37], p= 0.014) independent of IDH mutation
status (Supplementary Figure S2). Finally, average recur-
rence time in GBM IL-8-downregulated patients is sub-
stantially longer than in IL-8-upregulated patients (IL-8-
down 47.9 months, IL-8-up 15.5 months, hazard ratio
(HR)= 0.53 [0.34, 0.84], log-rank p-value= 0.006)
(Fig. 2e).
To investigate IL-8 expression patterns across different
tumor compartments, we utilized the Ivy Glioblastoma
Atlas Project (IVY GAP)14, which demonstrated that IL-8
mRNA is elevated in pseudopalisading cells and the
perinecrotic zone, two areas linked to the GIC sub-
population (Fig. 2f). All of these data further justify our
interest in IL-8 as a critical participant in GBM progres-
sion and therapy-induced plasticity.
Immunohistochemical analysis to IL-8 expression in
matched primary recurrent GBM tissue
To investigate IL-8 expression in GBM tissue from
patients, 75 GBM specimens from Northwestern Uni-
versity’s Brain Tumor Bank were subjected to immuno-
histochemical characterization. Pathological analyses
found 65% (49/75) of GBM samples were IL-8-positive.
Further, 17 matched primary and recurrent GBM tumor
pairs were examined for IL-8 expression. We found ele-
vated IL-8 in 65% (11/17) of recurrent tumors (Figs 3a–c).
Critically, IHC analysis revealed high IL-8 expression in
the typically hypoxic perinecrotic zone, an anatomical
compartment where GIC’s are maintained 11–14 (Fig. 2f).
Furthermore, both tumor cells and infiltrating macro-
phages express IL8 (Fig. 3d, e).
IL-8 receptor CXCR2+ GBM cells acquire CD133 expression
during anti-glioma chemotherapy
Next, we set to investigate how IL-8 signaling influences
GBM proliferation and cellular signaling. CXC motif
chemokine receptors 1 and 2 (CXCR1 and CXCR2) are
the major receptors for IL-815. To investigate their role in
IL-8-mediated signaling in GBM, we interrogated TCGA
data. We observed that expression of both these receptors
was significantly elevated in GBM tumors compared with
low-grade gliomas (Figure S2-A). Analysis of our ChIP-
seq data showed post-therapy accumulation of open
chromatin mark at a known enhancer site16 for CXCR2
(Fig. 4a, p-value < 0.0001), as well as significant decreases
in H3K27me3 levels in the gene body (Figure S2 C–H, p-
value < 0.001). In contrast, gene body H3K27me3 levels
were significantly increased at the CXCR1 gene locus
(Figure S2-B). FACS analysis for CXCR1/2 demonstrated
that all cell lines increased expression of both receptors
post-TMZ treatment. (Fig. 4b, p= 0.00015). CXCR2
expression was also elevated in the CD133+ GIC popu-
lation (Fig. 4c). Time course FACS following TMZ
treatment revealed that a CXCR2+ cell population exists
prior to TMZ treatment; this population rapidly gains
CD133 expression during treatment (Fig. 4d). CXCR1
expression was not altered during therapy (Fig. 4b and
Figure S2-I). Analysis of the downstream effectors of the
IL-8/CXCR signaling cascade in PDX GBM demonstrated
that IL-8 induces dose-dependent activation of canonical
ERK1/2 and AKT signaling (Figure S2-J).
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Fig. 2 Bioinformatic analysis reveals IL-8 as a potential participant in Glioblastoma progression and outcomes. a IL-8 mRNA expression levels
were analyzed using the Affymetrix U133a platform on the Cancer Genome Atlas (TCGA) for different WHO grades of glioma. GBM (Grade IV glioma)
patients had higher IL-8 expression level than low-grade (Grade II, Grade III) glioma patients. b All GBM patients were stratified into IL-8-upregulated
and IL-8-downregulated groups based on IL-8 gene expression using quartile (Q1, Q3) as split points. High expression of IL-8 correlated with reduced
median survival. Survival curves were generated via the Kaplan–Meier method and compared by log-rank test. **p < 0.01. Multivariate stepwise Cox
proportional hazards model with stepwise variable selection was conducted to examine whether IL-8 could be an independent factor for predicting
survival with major clinical variables adjusted. This analysis confirmed that IL-8 was an independent prognostic factor for survival in all GBM patients
(HR [95% CI]: all GBM 1.07 [1.01, 1.14], p= 0.0467). c Index (95% CI) or C statistics are provided. c Within grade IV glioma subtypes, proneural GBM
patients had the lowest level of IL-8 expression. Boxplots represent means and interquartile range. One-way ANOVAs with Bonferroni correction for
the multiple comparisons were performed. *p < 0.05, ***p < 0.001. d Patients with proneural GBM were stratified into IL-8-upregulated and IL-8-
downregulated groups based on IL-8 gene expression using quartile (Q1, Q3) as split points. Kaplan–Meier survival curves and multivariate stepwise
Cox proportional hazards models were generated as in B. e In TCGA database (U133a) GBM patients with IL-8-downregulated also have a longer time
to recurrence, compared with IL-8-upregulated patients. f The Ivy Glioblastoma Atlas Project (IVY GAP) was employed to determine the location of IL-
8 in glioblastoma samples. Each column represents the data for one biopsy from a tumor. Microdissection for the noted anatomically portions of the
tumor and subsequent mRNA extraction and expression analysis demonstrated that IL-8 is upregulated in the perinecrotic zone and
pseudopalisading cells. Heatmap illustrates most significantly and differential expressed genes with a false discovery rate < 0.01. mRNA expression in
each anatomical compartment were compared. IL-8 was significantly upregulated in the perinecrotic zone. Bars represent means from three
independent experiments and error bars represent the standard deviation. Multiple Student's t tests were performed. ***p < 0.001. g Brain tumor
samples from primary biopsies or surgical resections were stained for IL-8 at the Northwestern Brain Tumor Tissue Bank. Histological and
morphological analysis confirm that IL-8 is present in the perinecrotic zone and pseduopalisading cells. Scale bar 50 microns
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Fig. 3 Immunohistochemical analysis of IL-8 expression in the matched primary and recurrent GBM patient samples. a Representative
immunohistochemical staining for IL-8 in the matched primary (P) and recurrent (R) clinical GBM samples. Top row low-powered and bottom row
high-powered magnification of IL-8 staining. Scale bar for all top row images 1 mm, all middle row images 5 mm, and for the bottom row images
250 µm. These sets of patient samples show IL-8 upregulation in the matched recurrent tissues. b Same as previous, but this set of patient samples
shows a decrease in IL-8 staining for recurrent GBM as compared with their matched primary GBM. c Quantitative analysis of the percent of IL-8
positive cells in the matched primary and recurrent GBM tissue. Representative immunohistochemical analysis of IL-8 expressing (d) tumor cells (left,
black arrow) and (e) infiltrative macrophage (right, red arrow)
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IL-8 increases the self-renewing capacity of GBM cells and
the expression of GIC markers
To determine if the IL-8-CXCR signaling axis promotes
induction of the GIC state in GBM, we performed
extreme limiting dilution assay (ELDA) on GBM6 and
GBM43 cells in neurosphere media containing IL-8
(50 ng/ml). IL-8 increased GIC frequency about 3.3-fold
for GBM43 and 2.3-fold for GBM6 (Fig. 5a, p= 0.001).
Fig. 4 (See legend on next page.)
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We next examined how IL-8 alters the expression of
known GIC-promoting genes, using our proprietary GIC-
specific reporter cell line7. IL-8 activation significantly
increased reporter activity (Fig. 5b and Figure S3-A for
SOX2-RFP reporter and Nanog-RFP reporter p= 0.0005).
To investigate how the IL-8-CXCR signaling cascade
interacts with GIC-promoting genes in patient tumors, we
selected the top GIC-associated genes activated during
TMZ therapy (Fig. 1a and Supplementary Table 2) and
correlated with their levels with IL-8 mRNA using the
GlioVis data portal 16–18. IL-8 expression was sig-
nificantly correlated with critical GIC-associated genes,
including KLF4, CD44, HIF1A, HIF2A, Myc, and Twist
expression (Fig. 5c). Ivy Gap was used to explore colo-
calization of GIC-specific genes to IL8 expression within
tumor compartments. We observed that GIC-specific
genes were correlated with IL-8 expression in both the
perinecrotic zone and pseudopalisading cells (Fig. 5c,
heatmap; Ivy Glioblastoma Atlas Project.). Immunoblot
analysis of PDX lines exposed to IL-8 shows time-
dependent induction these genes (Fig. 5d) as well as var-
ious critical GIC-associated transcription factors, such as
C-myc, Nanog, Sox2, and OCT4 (Figure S3-D). Finally, to
examine the role of post-therapy IL-8 in inducing the
GIC-specific gene expression, we combined DMSO or
50 µM TMZ with either control IgG or anti-IL-8 neu-
tralizing antibody. Blocking of IL-8 both reduced basal
expression of GIC markers and prevented TMZ-induced
increases in SOX2 and C-Myc (Fig. 5e).
IL-8 enhances GBM growth and therapy resistance in vivo
To elucidate IL-8’s role during in vivo GBM growth,
U251 cells with stable IL-8 knockdown were established
using shRNA technology. IL-8 secretion was effectively
knocked down by two shRNA constructs (Figure S4-A and
B, p < 0.0005). Proliferation capacity was altered sig-
nificantly in cells with the highest IL-8 knockdown com-
pared with control population (Figure S4-C, p= 0.018),
but cell cycle profiles remained stable (Figure S4-D and E).
Athymic, immunodeficient mice then had GBM cells
expressing either sh-Control or anti-IL-8 shRNA#1
implanted into the right cerebral hemisphere. Each group
was then divided into two groups that received either
DMSO or TMZ (2.5 mg/kg, i.p.) (n= 7/group). IL-8
knockdown significantly increased the median survival of
animals with orthotropic GBM regardless of chemother-
apy exposure (Fig. 5f, first graph median survival sh-
control 38 days vs. sh#1 IL-8 140 days; hazard ratio of
survival= 4.737, 95% CI= 4.190 to 101.3, p= 0.0021). In a
clinically relevant model, PDX GBM43 (which express
high basal levels of IL-8, Fig. 1c and e) were infected with a
lentivirus carrying shRNA against IL-8, reducing IL-8
expression by 50% (Figure S6-A, p > 0.0005) after transient
transfection. Implantation of these IL-8 knockdown
GBM43 prolonged median survival about 38% compared
with control shRNA (Fig. 5f, 2nd graph median survival for
sh-control 29 days vs. sh#2 IL-8 40 days, p= 0.0003).
Moreover, IL-8 knockdown significantly enhanced the
therapeutic efficacy of TMZ and improved survival about
51 days (Fig. 5f).
IL-8 signaling promotes epigenetic alterations in GBM
To identify potential mechanisms by which IL-8 influ-
ences growth and promotes therapeutic resistance,
we analyzed correlations between IL-8 and 12042 other
genes using TCGA GBM patient data via Pearson corre-
lation coefficients. Our analysis returned 68 genes
with coefficients > 0.5 or <−0.5 and FDR < 0.05 that cor-
relate with IL-8; we then conducted unsupervised hier-
archical clustering. Observed cophenetic correlation
determined optimal clusters, which we validated by sil-
houette plots and principal component analysis (PCA).
Two clusters with the highest cophenetic coefficient at
0.95 and average silhouette width at 0.46 (Figure S5
and Fig. 6a) separated well upon visualization of PCA.
Using the Enrichr platform, we determined that the first
(see figure on previous page)
Fig. 4 Therapeutic stress alters epigenetic status and increases expression of CXCR2, one of the major receptors for IL-8. a ChIP-seq analysis
was performed for H3K27ac, a marker of open chromatin associated with activation of gene expression, and H3K27me, associated with closed
chromatin and repressed gene expression, on PDX GBM43 cells. Cells were treated with either TMZ (50 μM) or equimolar DMSO for 4 days prior to
analysis. Top track shows the location of the CXCR2 gene, with higher magnification analysis of the area shown below. TMZ-treatment led to
increased H3K27ac enrichment, including in a well-established enhancer region for CXCR2 (green box and red box) [Chr2:218714857–218715098, fold
enrichment 3.14 relative to IgG input, p-value < 0.0001, FDR 0.0004; Chr2:218714701–218715149, fold enrichment 3.63 comp. input, p < 0.0001, FDR <
0.0001]. Furthermore, gene body H3K27me3 was significantly reduced following TMZ [p= 00120 in TMZ relative to DMSO control levels]. b FACS
analyses were performed to determine how TMZ treatment alters the levels of CXCR2 in three GBM cell lines—GBM43, GBM6, and U251. Samples
were analyzed 8 days after initial treatment with either DMSO or TMZ (50 µM). All data are expressed as the mean fluorescent intensity (MFI). Bars
represent means from three independent experiments and error bars represent the standard deviation. Multiple Student's t tests were performed.
***p < 0.001. c Representative FACS scattered plot analyses from GBM43 cells treated with either DMSO or 50 µM TMZ across 8 days. Circle highlights
the clear shift of the CXCR2 expressing population into the CD133+ compartment. d TMZ treatment significantly increased expression of CXCR2 in
both GBM43 and GBM6, with CXCR2 expressing cells beginning to co-express CD133 GIC markers in a time-dependent manner. All data are
expressed as the percentage of total live cells. Bars represent means from three independent experiments and error bars represent the standard
deviation. Multiple Student's t tests were performed. **p < 0.01; ***p < 0.001
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of these clusters (Group A) is involved in regulating cell
chemotaxis (GO: 0060326, adjusted p-value 1.058e-11)
and cytokine activity (GO: 0005125, adjusted p-value
2.495e-9), well-established canonical roles for IL-817,18.
Cluster B includes genes enriched for wounding (GO:
009611, adjusted p-value 0.002) and hypoxia (GO:
0001666, adjusted p-value 0.004), also known IL-8
connections19,20. Interestingly, IL-8 signaling also
positively correlated with genes known to regulate epi-
genetic processes, specifically histone 3 lysine 27 tri-
methylation (H3K27me3) (GO: 0001666, adjusted p-value
0.03).
Trimethylation of H3K27 suppresses gene expression
via recruitment of the polycomb repressor complex
Fig. 5 IL-8 contributes to glioma-initiating cell phenotype and contributes to GBM growth in vivo. a Limiting dilution neurosphere assays
were performed on two cell lines—GBM43 and GBM6—after treatment with 50 ng/ml of IL-8. Stem cell frequency for GBM43 with IL-8 35.7, lower
limit 50.7 and upper limit 25.1 as compared with no IL-8 118.6, lower limit 169.2 and upper limit 83.1, p= 0.0156; for GBM6 with IL-8 27.1, lower limit
39.2 and upper limit 18.8 as compared with no IL-8 60.7, lower limit 85 and upper limit 18.8, p= 0.001. b To determine the ability of IL-8 to influence
cellular plasticity, we employed a reporter cell line in which RFP expression is controlled the OCT4 promoter. Cells were treated with 50 ng/ml of IL-8,
and RFP expression was monitored by FACS over 6 days. Treatment increased both Oct4 and Sox2. Bars represent means from three independent
experiments and error bars represent the standard deviation. Multiple Student's t tests were performed. **p < 0.01, ***p < 0.001. c The network of GIC-
promoting genes in patient tumors, we selected the top GIC-associated genes activated during TMZ therapy (Fig. 1a and Supplementary Table 2) and
correlated with their levels with IL-8 mRNA using the GlioVis data portal for visualization and analysis of brain tumor expression database (gliovis.
bioinfo.cnio.es; dataset LeeY) 16–18. IL-8 expression was significantly correlated with critical GIC-associated genes including KLF4, CD44, HIF1A, HIF2A,
Myc, and Twist expression (Fig. 5c). The IL-8 expression in different anatomical location and potential colocalization of these GIC-specific genes with
areas of high IL-8 transcript level (Fig. 5c, heatmap). d Immunoblot analysis of endogenous glioma-initiating cell-associated transcription factors
expression upon stimulation with escalation dose of IL-8 (0–100 ng/ml) for 24 h. Protein extracts of IL-8-treated PDX lines GBM43 and GBM6 were
immunoblotted with antibody against several GIC markers, including c-myc, Sox2, Nanog, KLF4, OCT4, or an antibody against β-actin as a control for
equal loading. e GBM43 PDX cells were treated with neutralizing antibody against IL-8 or control IgG antibody (100 ng/ml) prior to treatment with
DMSO or 50 µM TMZ. Neutralizing antibody was added every day for 8 days,and protein extracts from this experiment were immunoblotted with
antibody against c-myc, Sox2, OCT4, or an antibody against β-actin as a control for equal loading. f Schematic diagram of experiment design for
in vivo testing. Top graph, U251 cells were infect with lentivirus (Sigma Mission shRNA) shRNA against IL-8 or scrambled shRNA (control) with 10
infectious unit/cell. In total, 2 × 105 transduced cells were stereotactically injected into the right hemisphere of the brain of athymic nude mice (n= 8
per group, four males and four females). Two weeks after implantation, two groups of mice, control, and knock down, were treated with vehicle
treated (DMSO, top curve) or TMZ (2.5 mg/kg) intraperitoneally. Survival curves were obtained by the Kaplan–Meier method, and overall survival time
was compared between groups using log-rank test. All statistical tests were two-sided. Bottom graph, to examine the role of IL-8 in GBM progression
in a more clinically relevant manner, next the same method was used to knockdown the IL-8 expression in GBM43 PDX line. In total, 1.5 × 105 cells
were injected stereotactically into the right hemisphere of the brain of athymic nude mice (n= 8 per group, four males and four females). Survival
curves were obtained by the Kaplan–Meier method, and overall survival time was compared between groups using log-rank test
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Fig. 6 IL-8 signaling alters histone marks, promoting post-therapy epigenetic plasticity. a Correlation between IL-8 and 12042 genes from
TCGA was determined by Pearson correlation coefficients. Sixty-eight genes with coefficients > 0.5 or <−0.5 and false discovery rate (FDR) < 0.05
were selected. Unsupervised hierarchical clustering of those genes found two clusters with the highest cophenetic coefficient at 0.95 and an average
silhouette width at 0.46. Principal component analysis was used to validate these clusters. Enrichment analysis found one cluster of genes was
enriched at cell chemotaxis (GO: 0060326, adjusted p-value 1.058e-11) and cytokine activity (GO: 0005125, adjusted p-value 2.495e-9), while another
cluster of genes enriched at wounding (GO: 009611, adjusted p-value 0.002) and hypoxia (GO: 0001666, adjusted p-value 0.004). b Representative
immunoblot of different histone marks. A panel of PDX lines from a different subtype of GBMs was exposed to IL-8 (50 ng/ml) for 24 h. Nuclei were
extracted from the harvested cells and subjected to immunoblot analysis for suppressive histone marks H3K27 and H3K9 trimethylation (me3) and
activating mark H3K27 acetylation(ac). Immunoblotting for total histone three was performed to confirm the equal loading. c The extracted nuclei
from the U251 IL-8 knockdown cells as described in Fig. 5f were subjected to immunoblot analysis for various histone marks as described above.
d GBM43 cells were treated with IL-8 (50 ng/ml) for 2 and 24 h, cytoplasmic and nuclear extract was prepared, cells were harvested, and
immunoprecipitation assays were performed with the anti-EZH2 antibody. Immunoprecipitated protein was subjected to immunoblot analysis with
antibodies against phosphor-EZH2 (S21, and Thr345), and SUZ12. β-Actin and histone 3 were used as loading controls. e IL-8 (50 ng/ml)-treated
GBM43 PDX lines were harvested at 6, 12, and 24 h post IL-8 exposure. mRNA was extracted and subjected to reverse-transcription polymerase chain
reaction (RT-PCR) analysis of OLIG2, SERPINB2, IL6R, and BMP2K transcripts. Bars represent means from two experiments in triplicate and error bars
represent the standard deviation. Multiple Student's t tests were performed. **p < 0.01, ****p < 0.0001. f A panel of GBM PDX lines was treated with
TMZ (50 µM) for 48 h. Nuclei were extracted from the harvested cells and subjected to immunoblot analysis for suppressive histone marks H3K27me3
and H3K9me2 and activating mark H3K27ac and H3K4me3. Immunoblotting for total histone three was performed to confirm equal loading. g The
U251 IL-8 control and knockdown cells as described in Fig. 5a were treated with TMZ(50 µM) for 4 days. Nuclei were extracted from the harvested
cells and subjected to immunoblot analysis for suppressive histone marks H3K27me3 and H3K9me2 and activating mark H3K27ac. Left, representative
densitometry analysis is expressed as percent of control shRNA (shCtrl). h The GBM43 PDX line was treated with TMZ(50 µM) in the presence of 3-
deazaneplanocin A (DZNep, EZH2-I, 5 µmol/L), a histone methyltransferase EZH2 inhibitor for 8 days. Cells were harvested and the GIC population
was analyzed by FACS analysis of the CD133 and CD15 positive cells. Bars represent means from two experiments in triplicate and error bars
represent the standard deviation. Multiple Student's t tests were performed. ***p < 0.001
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(PRC), predominately regulated by two methyl-
transferases, EZH2 and G9a21,22. Confirming our in silico
result, treatment with IL-8 significantly increased tri-
methylation of H3K27, as well as another PRC complex
target, H3K923, in three PDX lines (Fig. 6b). Moreover,
reduction of IL-8 expression via shRNA abolished
methylation of the H3K27 and H3K9 residues (Fig. 6c),
with dose-dependent effects (Supplementary Figure S6-B).
To further elucidate the connection between IL-8 and
PRC, we examined the status of PRC members following
IL-8 exposure. Phosphorylation of EZH2 in response to
various extracellular stimuli remodels the epigenomic
landscape, allowing cellular adaptation24. Specifically,
phosphorylation at Thr345 enhances recognition of target
genes leading to recruitment of PRC2 and suppression of
transcription via H3K27me3.25 Contrastingly, extra-
cellular AKT signaling suppresses the methyltransferase
activity of EZH2 by phosphorylating Ser2126. Our pre-
vious results illustrated that IL-8–CXCR interaction could
activate various downstream signaling cascades, including
PI3K–AKT (Figure S6-C and D)27. We, therefore, exam-
ined the alteration of the phosphorylation status of EZH2
by IL-8 via immunoprecipitation (IP) in the nuclear and
cytoplasmic fraction (Fig. 6d). IL-8 stimulation enhanced
phosphorylation of EZH2 at both Ser21 and Thr345,
exclusively in the cytoplasmic fraction. However, within
2 h of IL-8 stimulation, S21-phosphorylated (inhibited)
EZH2 levels were decreased in the nucleus, while Thr345-
phosphorylated (activated) EZH2 accumulated. Binding of
EZH2 to SUZ12, an essential PRC protein, increased only
in the cytoplasmic compartment after IL-8 exposure,
while the nuclear accumulation of EZH2–SUZ12 complex
gradually decreased. We conclude that within 2 h of IL-8
exposure, the PRC2 activity may increase, but by 24 h
nuclear accumulation of PRC2 complex is reduced by
heightened phosphorylation of EZH2 at Ser21.
To determine the functional effect of IL-8 on EZH2
activity, we analyzed genes positively regulated by EZH2
(OLIG2, SERPINB2) and negatively regulated genes IL6R
and BMP2K via qRT-PCR (Fig. 6e)28. Remarkably, IL-8
exposure reversed expression of all four EZH2 target
genes, indicating that IL-8-induced EZH2 modifications
does alter gene transcription.
Next, we expanded our investigation into TMZ-induced
therapeutic stress-induced alterations in histone markers
that are targets of EZH2/PRC2. Treatment with TMZ
induced subtype- and time-dependent global changes in
epigenetic markers H3K27me3 and H3K9me3 and open-
chromatin marker H3K27 acetylation (ac) (Fig. 6f).
Additionally, PRC2 target H3K9me3 was upregulated in
GBM6. H3K27 trimethylation and acetylation were
upregulated within 48 h post-TMZ exposure and stayed
elevated. H3K4 trimethylation also increased within 96 h,
indicating acquisition of bivalency29.
Given that TZM induces IL-8 signaling and EZH2-
dependent changes in histone status, we next examined
the relationship between TMZ, IL-8, and EZH2 target
histones. We treated IL-8-knockdown cells with TMZ for
96 h and analyzed histone status. Reduced IL-8 levels
abolished methylation of EZH2 targets H3K27 and H3K9;
however, H3K27ac decrease was minimal. Consequently,
we suspect that chemotherapy-induced IL-8 signaling
participates in EZH2-dependent epigenetic modifications
during therapeutic stress. Finally, to investigate the role of
EZH2/PRC2 complex activity in promoting therapy-
induced cellular plasticity, the GBM43 PDX line was
treated with TMZ in the presence of 3-deazaneplanocin A
(DZNep, EZH2-I), a histone methyltransferase EZH2
inhibitor. DZNep abolishes the induction of a GIC
population after therapy, as measured by FACS analysis of
the CD133+ and CD15+ populations (Fig. 6h,
p > 0.0005).
Discussion
The ability of GBM cells to adapt to current therapies
and generate treatment-resistant recurrences represents a
critical challenge facing brain tumor researchers and
clinicians. Here, we provide data that illustrates new
mechanisms that may underlie this powerful ability to
react to and overcome standard of care therapies. This
study highlights the IL-8/CXCR2 signaling pathway as a
critical player in this process and a potential target for
blocking GBM cellular plasticity during therapy. Specifi-
cally, our data show: (1) therapeutic stress alters the epi-
genetic regulation of IL-8 leading to increased expression
and secretion of IL-8; (2) bioinformatics analysis and IHC
analysis of matched primary and recurrent patient tissues
suggest that IL-8 significantly influences patient progres-
sion and time to recurrence; (3) therapeutic stress-
induced IL-8 alters the phenotype of GBM cells, shifting
them to a more GIC-like state; (4) IL-8 supports GBM
aggression and resistance to chemotherapy in vivo; and
(5) IL-8 signaling may influence the acquisition of GIC
state via modulation of the histone modifying PRC2
complex.
Induction of cellular plasticity, is a well-established
player in the formation of GBM recurrence. Indeed, we
and several other groups have demonstrated how stan-
dard therapies can initiate this process and enrich GBM
tumors with GIC cells4,5,7,30. However, targetable players
in this process have yet to be identified. Here, we provide
evidence that IL-8 represents one such target. Our results
show that IL-8 is sufficient to induce the GIC state on its
own and that it is both adequate and necessary for the
adoption of GIC state during therapeutic stress.
These results highlight IL-8 signaling as a potent reg-
ulator of GBM phenotype. Not only was IL-8 able to
induce the expression of CD133 and CD15, two GIC
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phenotypic markers, it also caused increased expression of
many transcription factors known to promote the GIC
phenotype, including HIF, c-myc, Sox-2, and CD44. In
light of the ongoing debate regarding the precise gene
expression profile of GICs, this robust induction, com-
bined with our matched patient data, provides strong
evidence that IL-8 is capable of activating cell repro-
gramming toward a more GIC-like state during
chemotherapy.
Another key aspect of this study concerns the tumor
microenvironment and how therapy can influence its
composition. We show that GBM cells manipulate their
microenvironment following treatment with chemother-
apy. This fact further corroborates a growing body of
evidence that tumor cells cultivate a pro-growth micro-
environment. An interesting facet of our data is the fact
that culturing GBM cells in pro-GIC conditions alone led
to an increase in IL-8 levels, suggesting that tumor cells
may utilize positive-feedback loops to respond to their
surroundings rapidly, a potential new therapeutic target.
One open question from this study is potential non-tumor
sources of IL-8 in the tumor microenvironment. While our
results illustrate a robust role for GBM autocrine IL-8, it
remains an open question how IL-8 from surrounding non-
tumor cells might participate in the recurrence process.
Cytokines from the stroma and infiltrating immune cells
have been identified as regulators of tumor behavior in other
cancer types, including breast cancer31,32. Previous work has
shown that IL-8 signaling in the perivascular niche is critical
to GIC behavior and phenotype33. In fact, our IHC analysis
shows that infiltrating macrophage express IL-8 in the
tumor microenvironment. Moreover, astrocytes and brain
endothelial cells are both known to release cytokines,
especially in response to damage34–36. Indeed, one of the top
hits from our bioinformatics analysis of pathways correlated
with IL-8 expression in patient samples was wound healing.
These data and the potential involvement of non-tumor
cells provide further evidence for the theory that cancer
represents an “un-healing” wound and is caused by inap-
propriate activation of damage response and inflammatory
pathways. New research will shed light on this hypothesis. In
light of the fact that GBM is highly sensitive to changes in
the microenvironment2,37 and factors secreted by nearby
neurons38, it is highly possible that non-tumor IL-8 may
participate in the processes described here.
Another open question is the specific mechanisms
activating the production of IL8 during therapy. We have
previously reported that therapeutic stress activates
hypoxia inducible factor (HIF) signaling in GBM and
promotes cellular plasticity. Evidence exists that HIF
signaling can promote the synthesis and secretion of
cytokines, including IL839–41. The fact that IL-8 is
strongly correlated with HIF levels in patient samples
supports the idea that HIF and IL8 may also be linked in
GBM’s response to therapeutic stress. Another potential
mechanism driving IL8 induction is IKK-regulated tran-
scription, a key process shown to regulate responses to
chemotherapy in other cells42. Further research will illu-
minate the driving force of chemotherapy-activated IL8
induction and secretion.
Our data indicate for the first time that IL-8 is capable of
causing alterations in the epigenetic status of key gene
regulation factors, such as H3K27. While evidence
increasingly shows the importance of epigenetic regulation
in GBM growth and therapy resistance, the mechanisms
activating these processes remain incompletely understood.
IL-8 appears to act as one tumor-derived trigger for acti-
vating epigenetic responses to tumor therapy via modula-
tion of the canonical PRC2 complex.
In sum, our data show that IL-8 is a key micro-
environmental factor involved in promoting cellular
plasticity in GBM. Through analysis of murine models
and patient data, we illustrate the high degree of influ-
ence IL-8 holds over tumor progression. Furthermore,
our work connects IL-8 signaling to the increasingly
important area of epigenetic regulation of gene expres-
sion to allow tumor growth. These results highlight IL-8/
CXCR signaling as a key target for GBM drug develop-
ment, especially in combination with standard of care
therapies.
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